Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned an average recommendation of “Hold” from the twenty ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $123.28.

Several equities analysts have recently commented on ZBH shares. Royal Bank of Canada upped their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Evercore ISI lowered their price target on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $125.00 to $128.00 in a report on Tuesday. Wells Fargo & Company raised their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Barclays cut their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th.

Zimmer Biomet Price Performance

ZBH stock opened at $108.08 on Wednesday. Zimmer Biomet has a 1 year low of $101.47 and a 1 year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm has a market capitalization of $21.52 billion, a PE ratio of 20.55, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The business has a 50 day simple moving average of $107.90 and a 200-day simple moving average of $108.55.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the business earned $1.65 EPS. Equities research analysts anticipate that Zimmer Biomet will post 7.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ZBH. Dunhill Financial LLC boosted its stake in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $28,000. Bangor Savings Bank purchased a new position in Zimmer Biomet during the 3rd quarter worth approximately $31,000. Family Firm Inc. acquired a new position in Zimmer Biomet during the second quarter worth approximately $33,000. Finally, Brooklyn Investment Group purchased a new stake in Zimmer Biomet in the third quarter valued at approximately $35,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.